Biological Industries

Tissue Culture Products for Research and Diagnostics

Health Tech & Life Sciences
Acquired by Sartorius on May, 2019
Follow

Company Overview

Snapshot

Founded in December 1990, Biological Industries operates with 51–200 employees. The company was acquired by Sartorius in May 2019.

Business overview

Biological Industries is a global supplier within the life sciences industry, specializing in cell culture media development and manufacturing. The company provides a range of products including cell culture media, supplements, and reagents for stem cell research, cell therapy applications, and serum-free media. Serving the biopharmaceutical industry, universities, government research organizations, and healthcare institutions, Biological Industries operates within the Health Tech & Life Sciences sector, focusing on areas such as biomaterials, tissue engineering, and medical devices.

Strategic signal

In December 2019, Sartorius acquired a majority stake in Biological Industries, a move that significantly expanded Sartorius's cell culture media portfolio. This acquisition signals a strategic consolidation within the life sciences market, enhancing Sartorius's capabilities in cell culture and positioning Biological Industries' products within a larger global framework.

Log in to access full profile

Company Intelligence Q&A

What is Biological Industries' primary focus?
Biological Industries focuses on developing and manufacturing cell culture media, supplements, and reagents for research and diagnostic applications within the life sciences industry.
When was Biological Industries acquired?
Biological Industries was acquired by Sartorius in May 2019.
What was a key strategic partnership for Biological Industries USA in 2017?
In March 2017, Biological Industries USA signed an agreement with Mill Creek Life Sciences to add PLTMax Human Platelet Lysate to its stem cell portfolio.
What distribution deal did Biological Industries USA secure in June 2018?
In June 2018, Biological Industries USA added Vitronectin XF to its stem cell portfolio through an agreement with Primorigen Biosciences, Inc.
What initiative did Biological Industries USA announce in January 2018?
In January 2018, Biological Industries USA announced a.
Log in to access full profile